Meizi evolution
Upcoming SlideShare
Loading in...5
×
 

Meizi evolution

on

  • 1,256 views

Meizi evolution is promoted for weight loss and it contains sibutramine which was withdrawn from the market by 2010.

Meizi evolution is promoted for weight loss and it contains sibutramine which was withdrawn from the market by 2010.

Statistics

Views

Total Views
1,256
Views on SlideShare
1,256
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Meizi evolution Meizi evolution Presentation Transcript

  • FDA warns against “Meizi Evolution” P.Naina Mohamed Pharmacologist
  • Introduction The Food and Drug Administration (FDA) is advising consumers not to purchase or use “Meizi Evolution,” a product promoted and sold for weight loss on various websites, including www.ebay.com, and in some retail stores, on 27th June 2013. FDA laboratory analysis confirmed that Meizi Evolution contains sibutramine. Sibutramine is a controlled substance that was removed from the market in October 2010 for safety reasons.
  • Possible Mechanism of action Meizi evolution Contains Sibutramine Affects Ventromedial & lateral hypothalamic regions of CNS Blockade of Serotonin (5-HT), Noradrenaline and Dopamine reuptake Increase the neurotransmission of Serotonin (5- HT), Noradrenaline and Dopamine Rise of Satiety (Absence of hunger after eating) and reduction of hunger Loss of Appetite
  • Risks of Meizi Evolution Undeclared ingredient (Sibutramine) Inhibit the reuptake of mono amines (Serotonin, Noradrenaline and Dopamine) Increased neurotransmission of mono amines Elevated blood pressure and Heart Increased risk of Nonfatal myocardial infarction and nonfatal stroke in patients with preexisting cardiovascular diseases
  • Serious Drug Interactions Undeclared ingredient (Sibutramine) Interacts with Mono amine oxidase inhibitors (MAOIs) Inhibition of metabolism of monoamines Increased plasma level of monoamines Serious, sometimes fatal, reactions (“serotonin syndrome”) Excitement, hypomania, restlessness, loss of consciousness, confusion, disorientation, anxiety, agitation, motor weakness, myoclonus, tremor, hemiballismus, hyperreflexia, ataxia, dysarthria, incoordination, hyperthermia, shivering, pupillary dilation, diaphoresis, emesis, and tachycardia.
  • Other Drug Interactions Undeclared ingredient (Sibutramine) Interacts with Decongestants (Ephedrine or Pseudoephedrine) May raise blood pressure or heart rate
  • Other Drug Interactions Undeclared ingredient (Sibutramine) Interacts with CYP3A4 enzyme inhibitors like Ketoconazole, Erythromycin, etc. Increase the plasma level of Sibutramine Toxicity of Sibutramine
  • FDA Warnings FDA warns the Consumers should stop using this product immediately and throw it away. FDA advises the Consumers who have experienced any negative side effects should consult a health care professional as soon as possible. FDA announces to the public of a growing trend of dietary supplements or conventional foods with hidden drugs and chemicals. These products are typically promoted for sexual enhancement, weight loss, and body building, and are often represented as being “all natural.” FDA claims that they are unable to test and identify all products marketed as dietary supplements on the market that have potentially harmful hidden ingredients. FDA advises the Consumers to exercise caution before purchasing any product in the above categories.
  • FDA Warnings • FDA has requested market withdrawal after reviewing data from the Sibutramine Cardiovascular Outcomes Trial (SCOUT). SCOUT is part of a postmarket requirement to look at cardiovascular safety of sibutramine after the European approval of the drug. The trial demonstrated a 16 percent increase in the risk of serious heart events, including non-fatal heart attack, non-fatal stroke, the need to be resuscitated once the heart stopped, and death, in a group of patients given sibutramine compared with another given placebo. There was a small difference in weight loss between the placebo group and the group that received sibutramine. • RECOMMENDATION: Physicians are advised to stop prescribing Meridia to their patients, and patients should stop taking this medication. Patients should talk to their health care provider about alternative weight loss and weight loss maintenance programs. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhu manmedicalproducts/ucm228830.htm
  • References • http://www.fda.gov/Drugs/ResourcesForYou/Consum ers/BuyingUsingMedicineSafely/MedicationHealthFr aud/ucm358775.htm?source=govdelivery • CURRENT Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy, 2e Norton J. Greenberger, Richard S. Blumberg, Robert Burakoff • Clinician's Pocket Reference, 11e Leonard G. Gomella, Steven A. Haist • Harrison's Online Featuring the complete contents of Harrison's Principles of Internal Medicine, 18e • Basic & Clinical Pharmacology, 12e Bertram G. Katzung, Susan B. Masters, Anthony J. Trevor
  • References • http://www.fda.gov/safety/medwatch/safetyinfor mation/safetyalertsforhumanmedicalproducts/uc m228830.htm • http://www.tga.gov.au/safety/alerts-medicine- sibutramine-101008.htm • http://www.medsafe.govt.nz/hot/media/2010/Sib utramineOct2010.asp • http://www.bmj.com/content/340/bmj.c824